Phase II trial of the phosphatidyinositol-3 kinase (Pi3k) inhibitor buparlisib (Bkm120) in recurrent glioblastoma: An Ivy Foundation early phase clinical trials consortium study Meeting Abstract

   

Authors:	Wen, P.; Yung, A.; Mellinghoff, I.; Lamborn, K.; Ramkissoon, S.; Cloughesy, T.; Rinne, M.; Omuro, A.; DeAngelis, L.; Gilbert, M.; Chi, A.; Batchelor, T.; Colman, H.; Chang, S.; Nayak, L.; Massacesi, C.; DiTomaso, E.; Prados, M.; Reardon, D.; Ligon, K.
Abstract Title:	Phase II trial of the phosphatidyinositol-3 kinase (Pi3k) inhibitor buparlisib (Bkm120) in recurrent glioblastoma: An Ivy Foundation early phase clinical trials consortium study
Meeting Title:	4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)/18th Annual Meeting of the Society for Neuro-Oncology (SNO)
Journal Title:	Neuro-Oncology
Volume:	15
Issue:	Suppl. 3
Meeting Dates:	2013 Nov 21-24
Meeting Location:	San Francisco, CA
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2013-11-01
Start Page:	iii134
Language:	English
ACCESSION:	WOS:000327456200537
PROVIDER:	wos
DOI:	10.1093/neuonc/not182
PMCID:	PMC3823897
Notes:	Meeting Abstract: NO-145 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/51138